版权说明 操作指南
首页 > 成果 > 详情

Development of 11-DGA-3-O-Gal-Modified Cantharidin Liposomes for Treatment of Hepatocellular Carcinoma

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Zhou, Lili;Zou, Manshu;Zhu, Kun;Ning, Shuangcheng;Xia, Xinhua*
通讯作者:
Xia, Xinhua
作者机构:
[Xia, Xinhua; Zhou, Lili; Zou, Manshu; Ning, Shuangcheng; Zhu, Kun] Hunan Univ Chinese Med, Sch Pharm, Changsha 410208, Hunan, Peoples R China.
通讯机构:
[Xia, Xinhua] H
Hunan Univ Chinese Med, Sch Pharm, Changsha 410208, Hunan, Peoples R China.
语种:
英文
关键词:
3-galactosidase-30-stearyl deoxyglycyrrhetinic acid;asialoglycoprotein receptor;cantharidin;glycyrrhetinic acid;hepatocellular carcinoma;targeted liposomes
期刊:
Molecules
ISSN:
1420-3049
年:
2019
卷:
24
期:
17
基金类别:
National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81573621]; Hunan key research and development program [2017SK2122]
机构署名:
本校为第一且通讯机构
院系归属:
药学院
摘要:
BACKGROUND: Liver cancer is a common malignant tumor worldwide, and its morbidity and mortality increase each year. The disease has a short course and high mortality, making it a serious threat to human health. PURPOSE: The objective of this study was to create novel liver-targeting nanoliposomes to encapsulate cantharidin (CTD) as a potential treatment for hepatic carcinoma. METHODS: 3-Galactosidase-30-stearyl deoxyglycyrrhetinic acid (11-DGA-3-O-Gal)-modified liposomes (11-DGA-3-O-Gal-CTD-lip) for the liver-targeted delivery of CTD were prepared via the film-dispersion method and characteriz...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com